RNA-seq, ATAC-seq, and CRISPR Screening: Powering CAR T-Cell Research
Chimeric Antigen Receptor T-cell (CAR-T) approaches show great promise for therapeutic applications but are limited by cell exhaustion, an effect which reduces T-cell effectiveness against blood disorders. For the advancement of research in immune system modulation, CD Genomics offers professional services in RNA sequencing (RNA-seq), assay for transposase- accessible chromatin using sequencing (ATAC-seq), and CRISPR screening. Our advanced sequencing and bioinformatics solutions resolve challenges in chromatin accessibility, functional genomics, and the study of gene expression. This provides reliable insights needed to improve intervention strategies.
In this study, CD Genomics’ multi-omics platforms helped discover interleukin-4 (IL-4) as an important regulator of CART cell exhaustion. Our RNA-seq and ATAC-seq services revealed the transcriptional and epigenetic changes caused by IL-4, and CRISPR screening identified IL-4 signaling as a key pathway leading to CART cell dysfunction. These findings demonstrate how CD Genomics’ integrated solutions enable a greater understanding of CAR-T cell behavior, helping to develop methods for improving therapeutic potential.
For any other type of support, feel free to contact us
1-631-338-8059 | info@cd-genomics.com